tbuckley/cabot-search huggingface dataset:
Vanucizumab (VAN) in combination with atezolizumab (ATEZO) for platinum-resistant recurrent ovarian cancer (PROC): Results from a single arm extension phase of the phase I study BP28179
Authors: A. Oaknin, I. Vergote, I. Ray-Coquard, A. Leary, V. Rodriguez Freixinos, N. Concin, P. Toussaint, C. Massard, L. Fariñas-Madrid, E. Van Nieuwenhuysen, A. Lahr, I. Franjkovic, S. Rossomanno, P. Gerber, T. Nayak, F. Heil, C. Boetsch, A. Sahbi, K. Longauer, O. Krieter
Journal: Annals of Oncology (2017)
The Prostate Cancer Registry: Do patients with metastatic castration-resistant prostate cancer (mCRPC) differ according to metastatic status at diagnosis?
Authors: Simon Chowdhury, Alison J. Birtle, Anders Bjartell, Luis Costa, Susan Feyerabend, Luca Galli, Ewa Kalinka-Warzocha, Gero Kramer, Nicolaas Lumen, Pablo Maroto, Vsevolod B. Matveev, Thomas Paiss, Dominique Spaeth, Laurent Antoni, Edwin Klumper, Robert Wapenaar, Emma Lee
Journal: Journal of Clinical Oncology (2016)

5024 Background: The mCRPC patient population is heterogeneous, and clinical outcomes are influenced by clinical presentation and treatment history. Using the Prostate Cancer Registry (NCT02236637) database, we assessed whether the subset of mCRPC patients with metastatic (M) status at initial diagnosis represents patients with different clinical and disease characteristics in a real-life context. Methods: We report findings from the first 1323 consecutive patients in the Prostate Cancer Registry, a 3-year, prospective, observational study of the routine management of > 3000 patients with mCRPC across Europe. Results: Of the 1323 patients analyzed, 549 had distant metastases at initial diagnosis (M1, 41.5%), 526 did not (M0, 39.8%), and 248 were not evaluable (Mx, 18.7%). Conclusions: In this sample of 1323 men with mCRPC in routine practice, a higher percentage with M1 at diagnosis presented with aggressive and extended disease at mCRPC. M status at initial diagnosis may be a critical indicator of future treatment and prognosis in mCRPC, and follow-up of these patients over the course of the study will clarify how these differences and subsequent treatment may affect clinical outcomes. Characteristics. At initial diagnosis M stage M0 M1 Mx Patients, n 526 549 248 Mean (SD) patient age, years 73.6 (7.2) 70.6 (8.6) 74.2 (7.7) ≥ 75 years, n (%) 241 (45.8) 187 (34.1) 128 (51.6) Gleason score 8-10, n (%) 218 (44.6) 331 (66.5) 118 (52.7) Prior to study entry Years from diagnosis to CRPC, median (range) 6.2 (0-20) 2.4 (0-16) 5.5 (0-29) Years from first M diagnosis to study entry, median (range) 2.0 (0-15) 2.5 (0-13) 1.9 (0-11) Radical prostatectomy, n (%) 204 (38.8) 31 (5.6) 69 (27.8) Prostate radiotherapy, n (%) 300 (57.0) 49 (8.9) 84 (33.9) At study entry Prostate-specific antigen, ng/mL, median (range) 45.9 (0.0-5910.0) 61.7 (0.0-10710.0) 46.1 (0.0-2530.5) Bone lesions, n (%)a 0 49 (13.5) 8 (1.9) 14 (7.9) 1-20 208 (57.5) 228 (55.2) 110 (61.8) > 20 49 (13.5) 75 (18.2) 21 (11.8) ECOG PS, n (%)a 0-1 436 (87.2) 426 (83.4) 201 (87.4) 2 51 (10.2) 71 (13.9) 21 (9.1) Any analgesic therapy, n (%) 192 (36.5) 274 (49.9) 111 (44.8) SD, standard deviation. a Some patients not evaluable.
Comparable pharmacokinetics of 85 mg RightSize nilotinib (XS003) and 150 mg Tasigna in healthy volunteers using a hybrid nanoparticle-based formulation platform for protein kinase inhibitors.
Authors: Per Andersson, Mikael Von Euler, Michael Beckert
Journal: Journal of Clinical Oncology (2014)

e13551^ Background: Most of the protein kinase inhibitors (PKIs) have very challenging solubility properties and many products are suffering from pH dependent absorption, food effect and high variability leading to unmet medical needs [Di Gion et al.; Clin Pharmacokinet. 2011 Sep 50(9):551-603.]. We have earlier shown outstanding in vitro results with 8 different PKIs formulated with RightSize hybrid nanoparticles. The formulation improvments were verified in a preclinical dog model using Nilotinib [Jesson et al.; Pharm Res. 2013; http://dx.doi.org/10.1007/s11095-013-1191-4]. This clinical study compares XS003 containing Nilotinib to the originator product, Tasigna and is the first time a hybrid nanoparticle formulation is administered to humans. Methods: As part of a larger Phase 1 program, this pilot-study compared ascending doses of XS003 (85mg, 120mg and 150mg) and Tasigna 150mg in a four-period design in 9 healthy male volunteers. PK sampling occurred until 72h post-dosing. Results: XS003 was well tolerated. No SAEs occurred. Pharmacokinetic parameters of XS003 85 mg, 120 mg and 150 mg and Tasigna 150 mg are shown in the Table. Conclusions: Tasigna prescribing information states approximately 30% bioavailability (BA) of Nilotinib when taken fasted and 82% BA increase if taken with high fat meal. In this study, 85 mg XS003 is at point estimates bioequivalent with the 150 mg capsule of Tasigna. This matches the BA in fasted state for XS003 and indicates that an elimination of food effect could be feasible. Clinical trial information: Submitted.Pharmacokinetic Summary of Nilotinib following administration of 150 mg Tasigna and 85, 120 and 150 mg XS003. Period Number of subjects Estimate Tmax (h) Cmax (ng/mL) AUCinf (ng x h/mL) AUC24 (ng x h/mL) T1/2 (h) 1 Tasigna (150 mg) 9 GeoMean 4.5 420 9160 5490 15.6 CV% Geomean 18.1 28.4 35.3 25.1 52.4 2 XS003 (85 mg) 9 GeoMean 2.3 482 8010 5650 11.1 CV% Geomean 58.3 28.5 33.4 26.9 24.7 4 XS003 (120 mg) 6 GeoMean 3.3 604 11100 7420 12.3 CV% Geomean 31.8 26 30.6 23.3 18.1 3 XS003 (150 mg) 7 GeoMean 3.2 610 11900 7830 11.6 CV% Geomean 39.3 32.4 41.4 30.3 20.9
A Phase 3 Study of nivolumab (Nivo) in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Updated results and subset analysis by PD-L1 expression (ATTRACTION-02)
Authors: N. Boku, Y-K. Kang, T. Satoh, Y. Chao, K. Kato, H.C. Chung, J-S. Chen, K. Muro, W.K. Kang, T. Yoshikawa, S.C. Oh, T. Tamura, K-W. Lee, L-T. Chen
Journal: Annals of Oncology (2017)
Hepatic functional imaging and genomics to predict irinotecan pharmacokinetics and pharmacodynamics: The PREDICT IR study
Authors: M. Michael, W. Liauw, S-A. McLachlan, E. Link, A. Matera, M. Thompson, M. Jefford, R.J. Hicks, C. Cullinane, I. Campbell, P.J. Beale, C.S. Karapetis, T.J. Price, M.E. Burge
Journal: Annals of Oncology (2017)
Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial
Authors: Tomasz M Beer, Sebastien J Hotte, Fred Saad, Boris Alekseev, Vsevolod Matveev, Aude Fléchon, Gwenaelle Gravis, Florence Joly, Kim N Chi, Zafar Malik, Brent Blumenstein, Patricia S Stewart, Cindy A Jacobs, Karim Fizazi
Journal: The Lancet Oncology (2017)
GW28-e1022 Early Identification of Mutation Carriers in Familial of Young Hypertrophic Cardiomyopathy by Real-time 3D Speckle-Tracking Echocardiography
Authors: Qian Yang, Liwen Liu, Hong Wang, Xiaofeng Yang, Xiaodong Zhou, Shuping Ge
Journal: Journal of the American College of Cardiology (2017)
Interruption of measles transmission in Gipuzkoa (Basque Country), Spain
Authors: G Cilla, M Basterretxea, J Artieda, D Vicente, E Pérez-Trallero
Journal: Eurosurveillance (2004)

Measles vaccine was introduced in Gipuzkoa (Basque country, Spain) in 1978 and was replaced by the measles, mumps, and rubella (MMR) vaccine for children aged 12-15 months in 1981. A second dose of the MMR vaccine was introduced in 1992. Both doses of the MMR vaccine were well accepted by the population and high coverage was achieved (95% and 91% for the first and second doses respectively for the period 1993-2002). Measles virus circulation was interrupted in the second half of the 1990s: no cases of indigenous measles were notified between 1998 and 2003, and only imported cases have been confirmed during this period. These data indicate that the measles vaccination programme implemented has been effective. Nevertheless, to avoid measles outbreaks following viral introduction, high MMR vaccine coverage levels for the two doses have to be maintained (>95%).
Treatment beyond progression with nivolumab in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in the phase 3 checkmate 141 study: A biomarker analysis and updated clinical outcomes
Authors: R. Haddad, G. Blumenschein, J. Fayette, J. Guigay, A.D. Colevas, L. Licitra, S. Kasper, E.E. Vokes, F. Worden, N.F. Saba, M. Tahara, F. Concha-Benavente, M. Monga, M. Lynch, L. Li, J.W. Shaw, M.L. Gillison, K.J. Harrington, R.L. Ferris
Journal: Annals of Oncology (2017)
TRIUMPH Study: A multicenter Phase II study to evaluate efficacy and safety of combination therapy with trastuzumab and pertuzumab in patients with HER2-positive metastatic colorectal cancer (EPOC1602)
Authors: Y. Nakamura, W. Okamoto, K. Sawada, Y. Komatsu, K. Kato, H. Taniguchi, T. Kato, T. Nishina, T. Esaki, H. Nomura, M. Fukutani, M. Fukui, H. Hasegawa, M. Yonemura, N. Fuse, A. Sato, S. Fujii, A. Ohtsu, T. Yoshino
Journal: Annals of Oncology (2017)
AXL as a potential primary and secondary trastuzumab resistance mechanism in breast cancer cells with HER2 overexpression
Authors: J.M. Cejalvo, E. Tormo, A. Adam, F. Rojo, B. Pineda, S. Zazo, P. Gonzalez-Alonso, M. Sabbaghi, E. Alonso, A. Rovira, J. Albanell, B. Bermejo De Las Heras, O. Burgues, A. Lluch, J.A. Perez Fidalgo, P. Eroles
Journal: Annals of Oncology (2017)
Long-term responders to trastuzumab monotherapy in the first-line metastatic setting: characteristics and survival data (SAKK 22/99 Trial)
Authors: S. Schmid, D. Klingbiel, A. Goldhirsch, C. Oehlschlegel, E. Munzone, F. Nolè, B. Pestalozzi, S. Aebi, C. Rochlitz, R. von Moos, K. Zaman, C. Mamot, P. Weder, B. Thuerlimann, O. Pagani, T. Ruhstaller
Journal: Annals of Oncology (2017)
Unusual cause of opaque hemithorax
Authors: Satyajeet Sahoo, Manoj Kumar Panigrahi, Sourin Bhuniya, Prasanta Raghab Mohapatra
Journal: Thorax (2017)

A 40-year-old male presented with progressive breathlessness and hoarseness of voice. He denied any history of chest pain, cough, haemoptysis, palpitations or paroxysmal nocturnal dyspnoea. He was a smoker with 10 pack-year of smoking. His medical illness includes long-standing hypertension of 10 years duration controlled with oral amlodipine and atenolol. Previous echocardiography showed dilated and hypertrophied left ventricle with severe systolic dysfunction. At presentation, he was fully conscious with vitals as follows: heart rate 124/min, respiratory rate 34/min and blood pressure 110/70 mm Hg. All peripheral pulses were well felt. Chest examination revealed diminished movement of left hemithorax, reduced vocal resonance and breath sound with shift of mediastinum to right. Posteroanterior chest radiograph showed an opaque left hemithorax and a large retrocardiac opacity (arrows) with contralateral shift of mediastinum (figure 1A). Ultrasonography of thorax showed a large mixed echogenic lesion …
Chondroitin sulfate is superior to placebo in symptomatic knee osteoarthritis
Authors: Young Ho Lee
Journal: Annals of the Rheumatic Diseases (2017)

I read with great interest the article by Reginster and colleagues1 regarding the effectiveness of chondroitin sulfate (CS) in the treatment of symptomatic knee osteoarthritis (OA). This randomised, double-blind trial demonstrated that pharmaceutical-grade CS is superior to placebo and equivalent to celecoxib in reducing pain and improving function over 6 months in patients with symptomatic knee OA, indicating that this formulation of CS should be considered a first-line treatment in the …
Managers agree temporary cover after ambulance service collapses
Authors: Adrian O’Dowd
Journal: BMJ (2017)

Managers have secured a temporary agreement with a neighbouring ambulance trust following the collapse of a private ambulance service that was contracted to provide services for the NHS.

Private Ambulance Service Ltd, based in Essex, was issued with a winding-up notice by the Inland Revenue on 27 September. It will cease trading from 9 October.

Earlier this year, the company was awarded a contract by Bedfordshire, Luton, East and North Hertfordshire, and Herts Valley clinical commissioning groups (CCGs) to provide non-urgent patient transport services in their areas after the previous provider, Medical Services Limited, served notice to quit its contract early.

Since then, concerns have been raised by patients, the trade union UNISON, and some of the firm’s …
Correlation of somatic genomic alterations between tissue genomics and circulating tumor DNA (ctDNA) employing next generation sequencing (NGS) analysis in lung and gastrointestinal cancers
Authors: M.M. Toor, W. bahaj, Z. Ahmed, L. Kujtan, T.J. Pluard, M.E. McNally, L.S. Cummings, E. Island, J. Forster, K.F. Kennedy, J. Subramanian, A. Masood
Journal: Annals of Oncology (2017)
Deciphering the antitumor efficacy and mechanistic delineation of epigenetic inhibitors in AML using patient tumor derived ex vivo phenotypic assay based platform
Authors: P.K. Majumder, P. Radhakrishnan, S. Thiagarajan, M. Biswas, D.G. Malhotra, B. Ulaganathan, B. Majumder, G. Babu
Journal: Annals of Oncology (2017)
Efficacy and safety data in elderly patients (pts) with metastatic renal cell carcinoma (mRCC) included in the nivolumab expanded access program (EAP) in Italy
Authors: R. Sabbatini, L. Galli, S. Pignata, G. Lo Re, F. Valcamonico, C. Defferrari, M. Spada, D. Santini, C. Masini, L. Ciuffreda, E.M. Ruggeri, A. Chioni, L. Livi, D. Fagnani, A. Bonetti, L. Giustini, S. Duranti, G. Procopio, C. Caserta, G. Cartenì
Journal: Annals of Oncology (2017)
A matching-adjusted indirect comparison of trabectedin and pazopanib for the treatment of advanced, metastatic, leiomyosarcomas
Authors: R.L. Jones, J.-Y. Blay, A. Lecesne, J. Martin-Broto, M.J. Pontes, J.M. Fernandez Santos, B. García San Andrés, G. Wang, S. Wang, C.R. Shin, R. Maki, S. Patel, G.D.S. Demetri
Journal: Annals of Oncology (2017)
Comparison of progression-free survival (PFS) on comprehensive multiplatform profiling-guided therapy to PFS on prior therapy: A pooled analysis from 4 contemporary prospective studies
Authors: A. Seeber, G. Chahine, F. Nasr, A. Dean, M. Miranova, G. Jameson, N. Robert, G. Gastl, H. Zwierzina
Journal: Annals of Oncology (2017)
Cardiac MR With Late Gadolinium Enhancement in Acute Myocarditis With Preserved Systolic Function
Authors: Giovanni Donato Aquaro, Matteo Perfetti, Giovanni Camastra, Lorenzo Monti, Santo Dellegrottaglie, Claudio Moro, Alessia Pepe, Giancarlo Todiere, Chiara Lanzillo, Alessandra Scatteia, Mauro Di Roma, Gianluca Pontone, Martina Perazzolo Marra, Andrea Barison, Gianluca Di Bella
Journal: Journal of the American College of Cardiology (2017)
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
Authors: Jeffrey E. Gershenwald, Richard A. Scolyer, Kenneth R. Hess, Vernon K. Sondak, Georgina V. Long, Merrick I. Ross, Alexander J. Lazar, Mark B. Faries, John M. Kirkwood, Grant A. McArthur, Lauren E. Haydu, Alexander M. M. Eggermont, Keith T. Flaherty, Charles M. Balch, John F. Thompson
Journal: CA A Cancer Journal for Clinicians (2017)

Answer questions and earn CME/CNE To update the melanoma staging system of the American Joint Committee on Cancer (AJCC) a large database was assembled comprising >46,000 patients from 10 centers worldwide with stages I, II, and III melanoma diagnosed since 1998. Based on analyses of this new database, the existing seventh edition AJCC stage IV database, and contemporary clinical trial data, the AJCC Melanoma Expert Panel introduced several important changes to the Tumor, Nodes, Metastasis (TNM) classification and stage grouping criteria. Key changes in the eighth edition AJCC Cancer Staging Manual include: 1) tumor thickness measurements to be recorded to the nearest 0.1 mm, not 0.01 mm; 2) definitions of T1a and T1b are revised (T1a, <0.8 mm without ulceration; T1b, 0.8-1.0 mm with or without ulceration or <0.8 mm with ulceration), with mitotic rate no longer a T category criterion; 3) pathological (but not clinical) stage IA is revised to include T1b N0 M0 (formerly pathologic stage IB); 4) the N category descriptors "microscopic" and "macroscopic" for regional node metastasis are redefined as "clinically occult" and "clinically apparent"; 5) prognostic stage III groupings are based on N category criteria and T category criteria (ie, primary tumor thickness and ulceration) and increased from 3 to 4 subgroups (stages IIIA-IIID); 6) definitions of N subcategories are revised, with the presence of microsatellites, satellites, or in-transit metastases now categorized as N1c, N2c, or N3c based on the number of tumor-involved regional lymph nodes, if any; 7) descriptors are added to each M1 subcategory designation for lactate dehydrogenase (LDH) level (LDH elevation no longer upstages to M1c); and 8) a new M1d designation is added for central nervous system metastases. This evidence-based revision of the AJCC melanoma staging system will guide patient treatment, provide better prognostic estimates, and refine stratification of patients entering clinical trials. CA Cancer J Clin 2017;67:472-492. © 2017 American Cancer Society.
Pre-treatment neutrophil lymphocyte ratio/platelet lymphocyte ratio as surrogate markers of survival in non-metastatic head and neck cancer patients: An observational study
Authors: V. Agarwal, R. Rao, H.R. Abin, V. Rao, R.C. Nayar, V. Mani, A. Ram, B.S. Ajaikumar
Journal: Annals of Oncology (2017)
Genomics of Immunotherapy-Associated Hyperprogressors—Letter
Authors: Andrea Forschner, Heike Niessner, Yvonne Möller, Peter Horak, Martina Fröhlich, Gregor Warsow, Albrecht Stenzinger, Stefan Fröhling, Hanno Glimm, Bernhard Klumpp, Claus Garbe, Tobias Sinnberg
Journal: Clinical Cancer Research (2017)

Kato and colleagues ([1][1]) reported 4 cancer patients with metastatic disease, hyperprogression under treatment with anti-PD-1/PD-L1 monotherapy, and a cooccurring MDM2/4 amplification in the cancer cells. They defined hyperprogression as time-to-treatment failure  50% increase in tumor
Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitis
Authors: C. Franklin, I. Rooms, M. Fiedler, H. Reis, L. Milsch, S. Herz, E. Livingstone, L. Zimmer, K.W. Schmid, U. Dittmer, D. Schadendorf, B. Schilling
Journal: Annals of Oncology (2017)
The observational ENCORE study: Cetuximab + platinum-based therapy (PBT) for first-line (1L) treatment of patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
Authors: C. Le Tourneau, M. Ghiani, M.C. Cau, R. Depenni, G. Ronzino, L. Livi, V. Montesarchio, M. Bretagne, M. Saint-Ghislain, J. Schulten, D. Messinger, A. Sbrana, M.G. Ghi
Journal: Annals of Oncology (2017)

Background: The randomized, phase 3 EXTREME study established cetuximab + platinum + 5-flurouracil (5-FU) followed by cetuximab maintenance until progressive disease (PD) as the first regimen to yield survival benefits in the 1L management of patients with R/M SCCHN. In EXTREME, the addition of cetuximab increased the overall response rate from 20% to 36%, and extended progression-free survival from 3.3 to 5.6 months and overall survival from 7.4 to 10.1 months. ENCORE is a multinational, non-interventional, prospective, open-label study, seeking to determine how treatment decisions are made, planned and executed by oncologists treating patients with 1L therapy for R/M SCCHN in the real world. Methods: ENCORE prospectively enrolled 219 patients with R/M SCCHN from Algeria, France, Italy, Portugal and Russia. The recommended treatment for these patients is cetuximab + PBT for up to 6 cycles followed by cetuximab maintenance until PD. Patient characteristics, drugs and schedule were recorded; as the study is still ongoing, safety and efficacy will not be reported here. Results: ENCORE patients and the EXTREME patients who received cetuximab + platinum + 5-FU had similar performance status (PS: 13.7 and 12% with PS ≥ 2, respectively), but dissimilar median age (64 and 56 years, respectively). In ENCORE, 94.1% of patients had a planned treatment of cetuximab + PBT with cetuximab maintenance until PD. The remaining 13 (5.9%) had a fixed treatment duration of 4 to 24 weeks. 37.9% of treatment plans used cisplatin, 61.6% included carboplatin and 3.2% used a taxane. Also, only 53.4% of plans included 5-FU. When developing the treatment plan, 72.1% of all patients were discussed within the context of a multidisciplinary team (MDT). Most plans had the goal of palliative care, and 80% were formulated without a p16 or human papillomavirus status test. Updated data will be presented at congress. Conclusions: The ENCORE study shows that a real-world R/M SCCHN patient population treated with the EXTREME regimen has diverse characteristics and is treated per current recommendations (e.g. in an MDT setting, with cetuximab until PD). Clinical trial identification: EMR 62202-566 Legal entity responsible for the study: Merck KGaA, Darmstadt, Germany Funding: Merck KGaA, Darmstadt, Germany Disclosure: C. Le Tourneau: Consultancy: Novartis, MSD, Bristol-Myers Squibb, AstraZeneca; Honoraria: Merck Serono J. Schulten: Full Time Employee: Merck KGaA. D. Messinger: Employee/Consultancy: Employee of Prometris GmbH, which has a contract with Merck KGaA regarding statistical consultancy. All other authors have declared no conflicts of interest.
Biological assessment of viable germ cell tumor (VT) in patients (pts) with seminoma (S) and non-seminoma (S) using miR371
Authors: L. Nappi, M. Thi, L. Fazli, K. Chi, B. Eigl, C. Nichols, M. Gleave, C.K. Kollmannsberger
Journal: Annals of Oncology (2017)
GW28-e0719 The aortic remodeling comparative study of contrast enhanced ultrasound and CTA in DeBakey type III aortic dissection after TEVAR
Authors: Zhu Liang, Lin ShuiHua, Zhang Yuanxian, Jia Guoliang, Wang Bin, Zhu Yonghong
Journal: Journal of the American College of Cardiology (2017)
Gatekeeping Strategies for Avoiding False-Positive Results in Clinical Trials With Many Comparisons
Authors: Kabir Yadav, Roger J. Lewis
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reply to Julie Steinestel, Christof Bernemann, Andres J. Schrader, and Jochen K. Lennerz's Letter to the Editor re: Emmanuel S. Antonarakis, Changxue Lu, Brandon Luber, et al. Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men with Metastatic Castration-resistant Prostate Cancer Treated with First- and Second-line Abiraterone and Enzalutamide. J Clin Oncol 2017;35:2149–56. AR-V7 Testing: What's in it for the Patient?
Authors: Jun Luo, Brandon Luber, Hao Wang, Emmanuel S. Antonarakis
Journal: European Urology (2017)